Small molecules

Cancer research
#Diabetes #GLP-1 #Korea #Obesity #Phase I trial #Small molecules #Yunovia

Small molecule GLP-1 agonist shows superior tolerability

Yunovia (a subsidiary of Ildong Pharmaceutical Group) has received permission from the Ministry of Food and Drug Safety (MFDS) of Korea to begin a Phase I study for its small molecule glucagon-like peptide-1 (GLP-1) agonist for obesity and diabetes. The Phase I Multiple Ascending Dose (MAD) study will be conducted… Read More

#Editor's Choice #News #Regulatory

#Genomics #RNA biology #RNA Therapeutics #Serna Bio #Small molecules #Transcriptomics

The untapped potential of the transcriptome  

Serna Bio was founded by Rabia Khan, who is also the CEO, to unlock the transcriptome as a drug discovery target. DDW’s Megan Thomas speaks to Khan about the work her team is doing to create the first map of the druggable transcriptome, which involves understanding RNA biology to discover… Read More

#Exclusive Content #Opinion

Cancer cells
#Funding #Immunotherpy #NeoPhore #Proteins #Small molecules

Financing extension for neoantigen immuno-oncology company 

NeoPhore has announced a further extension of £9.6 million (approximately $12.2 million) to its Series B financing round, bringing the total raised to £31.1 million (approximately $39.5 million).  The company is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (MMR) pathway to generate… Read More

#Business & Investment #Cancer Research #News

Fibrosis lungs
#Fibrocor Therapeutics #Fibrosis #Fibrotic disease #Small molecules #Therapeutics

Fibrosis research: Advances and challenges 

Fibrocor Therapeutics, a developer of novel therapeutics to treat fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research.   MT:… Read More

#Exclusive Content #Opinion

Medical laboratory
#Annexon #Autoimmune disease #Phase I trial #Small molecules

Positive Phase I results for small molecule complement inhibitor

Biopharmaceutical company Annexon has reported promising results from its Phase I single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502. ANX1502 is a first-in-kind oral, selective small molecule inhibitor that targets the active form of C1s responsible for propagating classical pathway… Read More

#News

#Biologics #GlobalData #Inflammatory Bowel Disease #Market reporting #Small molecules

Biologics for bowel disease face threat from cheaper small molecules

The total sales of inflammatory bowel disease (IBD) drugs are estimated to reach approximately $10.2 billion in the US in 2023, according to analysts. The increase in IBD biologic treatments has been a major driving force in the growth of this market in recent years. In 2007, AbbVie’s Humira received… Read More

#Market Reports #News

Eye health ophthalmology
#Clinical trials #Diabetes #Exonate #Eye health #mRNA #Ophthalmology #Small molecules

Trial in diabetic macular oedema successfully completed  

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study.   During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity. Exonate… Read More

#News

Predicting analgesic compounds based on a two amino acids peptide to treat chronic pain.
#Chronic pain #New York University #Painkillers #Preclinical investigations #Small molecules

NYU scientists discover promising new candidate for pain treatment

A new compound reversed four types of chronic pain in animal studies, according to research led by New York University (NYU) College of Dentistry’s Pain Research Center. The small molecule, which binds to an inner region of a calcium channel to indirectly regulate it, outperformed gabapentin… Read More

#News

#Drug development #Generics #Patent Law #Pharmaceuticals #Polymorphism #Small molecules

Polymorph profiling with X-ray powder diffraction protects patents and patients

By Dr Natalia Dadivanyan, Segment Marketing Manager, Malvern Panalytical  Small molecules can face big challenges  Despite the emergence of, and excitement around, advanced therapeutic modalities, traditional small molecule pharmaceuticals still occupy a significant and steadily growing share of the market. A recent report indicated the current market size to be ~$166… Read More

#Business & Investment #Exclusive Content

The research team from the University of Illinois
#AI #Artificial intelligence (AI) #Automation / robotics #Biochemistry #Small molecules

New AI system could speed up drug discovery

A new system utilising artificial intelligence (AI), ‘building-block’ chemistry and a molecule-making machine could speed up innovation and drug discovery, as well as make complex chemistry automated and accessible. Researchers at the University of Illinois Urbana-Champaign and collaborators in Poland and Canada doubled the average yield of a special, hard-to-optimise… Read More

#News

#Drug discovery #Neurology #Small molecules

Sosei teams up with Abbvie on neurological drug discovery  

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases.   The agreement will see the companies combining their expertise and capabilities in neuroscience to discover and develop small molecules that modulate G protein-coupled… Read More

#News

#Oncology #Small molecules

Lead Pharma and Oxeltis receive €800K for cancer project  

Two life sciences companies have been awarded an €800K grant for their work developing a small molecule therapy for a fast-growing blood cancer.  Lead Pharma and Oxeltis were awarded the funding from EUREKA Eurostars for their three-year EPIGENEXT joint project.   Through the project,… Read More

#News

#Cambridge Innovation Park #Small molecules

Optibrium expands headquarters in Cambridge, UK  

Developer of software for drug discovery Optibrium has expanded its UK headquarters by moving to a larger space of Cambridge Innovation Park North.   Located in one of the UK’s leading technology hub, Optibrium’s new headquarters will provide new offices, meeting rooms, social areas and on-site leisure activities… Read More

#News

#AI #Drug discovery #Small molecules

X-Chem launches small molecule discovery platform

Artificial intelligence (AI) company X-Chem has announced that its drug discovery platform XD3 is now available to biopharma partners and clients. XD3 is the company’s small molecule drug discovery platform and combines data generated through DNA-encoded library (DEL) screening, along with analytical and predictive capabilities offered by A-Chem’s AI platform,… Read More

#News

#Brain disease #Cancer #Oncology #Small molecules #Therapeutics #Tumours

Hemispherian’s epigenetic therapeutics act on a new mechanism of action

Hemispherian is a Norwegian pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. Lu Rahman spoke to Zeno Albisser, CEO, to find out more about the company’s expertise.  LR: What it does Hemispherian do?  ZA: We are focused on developing a novel class of small molecule drugs (GLIX)… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biochemistry #Drug discovery #Drug targets #Mass spectrometry / NMR #Small molecules #Therapeutics

OMass unveils drug discovery pipeline for validated targets 

OMass Therapeutics has shared its pipeline of five novel, differentiated small molecule drug programmes, targeting intractable or inadequately drugged membrane and complex-bound protein targets such as GPCRs (G-protein-coupled receptors), solute carriers and intracellular protein complexes.  The company’s selected programmes focus on validated targets in immunology & rare disease indications with high unmet need. Read More

#News